Publications by authors named "A M MANDL"
Article Synopsis
- High-dose intravenous vitamin C (HDIVC) was tested alongside docetaxel in a clinical trial for patients with advanced prostate cancer, showing no significant benefit compared to docetaxel alone.
- The trial involved 47 participants and measured effectiveness through PSA response rates, overall survival, and quality of life, with similar outcomes in both the HDIVC and placebo groups.
- The study was halted early due to no evidence that HDIVC improved cancer treatment results, suggesting it shouldn’t be routinely used for metastatic castration-resistant prostate cancer.
Article Synopsis
- Lysine-specific demethylase 1 (LSD1) plays a key role in the progression of metastatic castration-resistant prostate cancer (mCRPC), particularly in its neuroendocrine form (NEPC), highlighting the need for effective LSD1 inhibitors like bomedemstat for treating these cancers.
- Bomedemstat was evaluated using various scientific methods, showing it is an irreversible inhibitor of LSD1 with significantly higher specificity over monoamine oxidase enzymes, and it effectively reduces tumor growth in prostate cancer models.
- The study found that bomedemstat accumulates well in tumors after oral administration and has an overall tolerable safety profile with manageable side effects, supporting its clinical
Article Synopsis
- Lysine-specific demethylase 1 (LSD1) plays a crucial role in tumor progression in metastatic castration-resistant prostate cancer (mCRPC), particularly in the aggressive neuroendocrine subtype (NEPC) that shows resistance to typical therapies.* -
- The study found that elevated LSD1 levels in NEPC correlate with poor clinical outcomes, and using the LSD1 inhibitor bomedemstat resulted in significant tumor regression in various cancer models.* -
- Mechanistically, LSD1 inhibition was shown to disrupt key interactions that suppress a neuronal transcriptional program, highlighting the potential of LSD1 inhibitors as a promising treatment strategy for aggressive mCRPC types.*
Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Expert Opin Investig Drugs
March 2023
Introduction: The bromodomain and extraterminal (BET) family of proteins are epigenetic readers of acetylated histones and are critical activators of oncogenic networks across many cancers. Therapeutic targeting of BET proteins has been an attractive area of clinical development for metastatic castration-resistant prostate cancer. In recent years, many structurally diverse BET inhibitors have been discovered and tested.
View Article and Find Full Text PDFGastroenteropancreatic neuroendocrine tumors (GEP-NETs) may occur in 30% to 90% of patients with multiple endocrine neoplasia type 1 (MEN1). However, only 1% of GEP-NETs are grade 3 (G3). Given the rarity of these aggressive tumors, treatment of advanced G3 GEP-NETs in MEN1 is based on the treatment guidelines for sporadic GEP-NETs.
View Article and Find Full Text PDF